文献速递脑血管病

非心源性急性卒中患者治疗性诱导高血压研究

Therapeutic-induced hypertension in patients with noncardioembolic acute stroke.
PubMed 文献 · Neurology · 2019-10-23

这项多中心随机临床试验纳入发病24小时内不适合血管再通治疗的非心源性急性缺血性卒中患者及住院期间进展性卒中患者,干预组静脉给予去氧肾上腺素使收缩压升至200 mmHg。校正年龄和初始卒中严重度后,诱导高血压提高了早期神经功能改善和90天功能独立的比例,且安全结局无显著组间差异。

要点

  • 去氧肾上腺素诱导高血压可提高非心源性急性卒中早期神经功能改善概率。
  • 诱导高血压组90天功能独立(mRS 0-2)比例显著高于对照组。
  • 症状性颅内出血/水肿、心肌梗死和死亡等安全结局无显著组间差异。

核心结论

  • 在不适合血管再通治疗的非心源性卒中及进展性卒中患者中,去氧肾上腺素诱导高血压安全,并带来早期神经功能改善和长期功能独立。

研究设计与样本

  • 多中心随机临床试验,干预组76例和对照组77例纳入改良意向治疗分析。
  • 纳入发病24小时内不适合血管再通治疗的非心源性急性缺血性卒中患者及住院期间进展性卒中患者。
  • 干预组静脉给予去氧肾上腺素,将收缩压提升至200 mmHg。

主要发现

  • 校正年龄和初始卒中严重度后,诱导高血压提高主要终点(OR 2.49,95%CI 1.25-4.96,p=0.010)。
  • 校正后诱导高血压提高次要终点(OR 2.97,95%CI 1.32-6.68,p=0.009)。
  • 安全结局(症状性颅内出血/水肿、心肌梗死、死亡)组间无显著差异。

关键数值与推荐

  • 主要疗效终点为前7天内NIHSS评分降低≥2分的早期神经功能改善。
  • 次要疗效终点为90天改良Rankin量表评分0-2分。
  • 干预目标为收缩压升至200 mmHg。

临床怎么用

  • 对于不适合血管再通治疗的非心源性急性缺血性卒中及进展性卒中患者,可考虑去氧肾上腺素诱导高血压以改善早期神经功能和长期功能独立。

局限性

  • 研究提供III级证据。
  • 样本量较小(干预组76例、对照组77例)。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To evaluate the safety and efficacy of induced hypertension in patients with acute ischemic stroke. METHODS: In this multicenter randomized clinical trial, patients with acute noncardioembolic ischemic stroke within 24 hours of onset who were ineligible for revascularization therapy and those with progressive stroke during hospitalization were randomly assigned (1:1) to the control and intervention groups. In the intervention group, phenylephrine was administered intravenously to increase systolic blood pressure (SBP) up to 200 mm Hg. The primary efficacy endpoint was early neurologic improvement (reduction in NIH Stroke Scale [NIHSS] score of ≥2 points during the first 7 days). The secondary efficacy endpoint was a modified Rankin Scale score of 0 to 2 at 90 days. Safety outcomes included symptomatic intracranial hemorrhage/edema, myocardial infarction, and death. RESULTS: In the modified intention-to-treat analyses, 76 and 77 patients were included in the intervention and control groups, respectively. After adjustment for age and initial stroke severity, induced hypertension increased the occurrence of the primary (odds ratio 2.49, 95% confidence interval [CI] 1.25-4.96, p = 0.010) and secondary (odds ratio 2.97, 95% CI 1.32-6.68, p = 0.009) efficacy endpoints. Sixty-seven (88.2%) patients of the intervention group exhibited improvements in NIHSS scores of ≥2 points during induced hypertension (mean SBP 179·7 ± 19.1 mm Hg). Safety outcomes did not significantly differ between groups. CONCLUSION: Among patients with noncardioembolic stroke who were ineligible for revascularization therapy and those with progressive stroke, phenylephrine-induced hypertension was safe and resulted in early neurologic improvement and long-term functional independence. CLINICALTRIALSGOV IDENTIFIER: NCT01600235. CLASSIFICATION OF EVIDENCE: This study provides Class III evidence that for patients with acute ischemic stroke, therapeutic-induced hypertension increases the probability of early neurologic improvement.

来源:Neurology,查看原文。版权归原作者所有。

引用

  1. Bang OY, Chung JW, Kim SK, et al. Therapeutic-induced hypertension in patients with noncardioembolic acute stroke. Neurology. 2019. PMID: 31645472. doi:10.1212/WNL.0000000000008520

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。